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Exhaled nitric oxide in the diagnosis of childhood asthma
A small but important piece of the clinical jigsaw
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Although asthma is the most common chronic disease 
of childhood,1 it remains a clinical diagnosis.2 Common 
symptoms include recurrent wheezing, cough, difficulty in 
breathing, and chest tightness, but no agreed “gold stand-
ard” definition exists.2 Improvements in symptoms and 
lung function seen after adequate treatment often provide 
retrospective confirmation of the diagnosis.2
Accurate diagnosis of asthma in children may be dif-
ficult but is vital for two reasons. Firstly, a correct diag-
nosis is essential for the institution of guideline based 
treatment, which may involve specialist referral; this is 
needed to avoid the morbidity and rarely mortality associ-
ated with poorly controlled disease.2 Secondly, the exclu-
sion of asthma prevents potential harm from inappropriate 
anti-asthma treatment and may highlight other crucial 
diagnoses such as cystic fibrosis.3
Asthma is a heterogeneous disease, and data from large 
population based studies have informed the concept of dif-
ferent patterns or “phenotypes” in children who wheeze.4 
Importantly, preschool children who wheeze only when 
they have viral respiratory tract infections form a discrete 
and largely self resolving group in which wheeze is inde-
pendent of allergic sensitisation.4 Wheeze associated with 
multiple triggers and allergic sensitisation, recognised as 
the “classic” atopic asthma phenotype, is responsible for 
most clinically important disease in school aged children 
but may also be relevant in younger life.4
Eosinophilic airway inflammation is the dominant 
pathology in atopic asthma, and anti-inflammatory drugs 
are the maintenance treatment of choice.2 5 However, only 
a weak correlation exists between airway inflammation 
and conventional measures of disease status, such as lung 
function or symptoms.5 This raises the important question: 
is it better to assess a child on the basis of improvement of 
symptoms or lung function or a reduction in inflammation, 
or even a combination of these?
Some studies in adults with asthma show that treatment 
aimed at normalisation of sputum eosinophils reduces 
exacerbations without the need to increase anti-inflam-
matory drugs.6 Any extrapolation to children should be 
done with caution, but it makes sense to try to measure 
some aspect of airway inflammation to aid clinical decision 
making.5-7 Such a test or “inflammometer” should ideally 
be non-invasive, safe, practical, reproducible, accurate, 
and cost effective.7
Airway eosinophils can be measured in children with 
the aid of bronchoscopy, so that bronchoalveolar lavage or 
endobronchial biopsy can be performed, or by the induc-
tion of sputum using nebulised saline. Bronchoscopy is 
invasive and normally requires a general anaesthetic. 
Induction of sputum requires cooperation from the child 
and support from laboratory staff. Sputum induction may 
also provoke substantial bronchoconstriction, and cells 
from the proximal airway are likely to predominate.7 8 
Nonetheless, the cytology of airway samples may provide 
evidence of eosinophilic or neutrophilic inflammation that 
can usefully guide treatment.8
Nitric oxide is formed in the airways by a reaction cata-
lysed by nitric oxide synthases.5 The expression of induc-
ible nitric oxide synthases is increased in inflammation, 
and the fractional concentration of exhaled nitric oxide 
(FeNO) is raised in atopic asthma.5 FeNO has therefore 
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attracted a great deal of attention as a potential non-inva-
sive measure of airway inflammation in childhood asthma.5 
In children with atopic asthma, this measure correlates best 
with eosinophil counts in steroid naive children in sputum 
or bronchoalveolar lavage but less well with mucosal eosi-
nophils in endobronchial biopsies.7 9 Importantly, several 
non-disease factors such as diet, age, race, time of day, 
and repeatability affect the measurements.5 Also, FeNO is 
raised in children with atopy, irrespective of the presence 
or absence of asthma.9 This suggests that complex inter-
associations exist between FeNO, eosinophils, and clinical 
asthma.9 However, high FeNO in the presence of symptoms 
of asthma is suggestive of steroid responsive eosinophilic 
inflammation.6
A recent study measured FeNO and the percentage of 
eosinophils in induced sputum, in addition to carrying out 
spirometry, in 150 consecutive white children with a mean 
age of 12 years, who were referred to a respiratory clinic 
for evaluation of possible asthma.10 Children with eczema 
or allergic rhinitis were included, but those with other 
“systemic manifestations of atopy,” such as food allergy, 
were excluded. After 18 months of follow-up, 69 children 
were diagnosed retrospectively by conventional criteria 
(two or more wheezing episodes documented by a doctor; 
dy spnoea or cough relieved by bronchodilators; bronchodi-
lator reversibility or variability in lung function over time 
with or without controller drugs but blind to FeNO and spu-
tum eosinophil results) as having steroid naive asthma, 37 
as having asthma already being treated with inhaled cor-
ticosteroids, and 44 as not having asthma. The sensitivity, 
specificity, positive predictive value, and negative predic-
tive value of FeNO and sputum eosinophils depended on 
the cut-off values used but compared favourably to forced 
expiratory volume in one second (table). However, appli-
cation of the best cut-off levels placed 10.6% of children 
with asthma in an inconclusive “borderline” category. 
This study was performed in a selected population with a 
clinical suspicion of asthma. In reality, forced expiratory 
volume in one second is not considered in isolation from 
the many other factors used to diagnose asthma.
Advocates for the use of FeNO in childhood asthma 
argue that the context is crucial, with clinical usefulness 
being greatest in the specialist clinic.7 FeNO should be 
viewed as complementary to conventional history tak-
ing, examination, spirometry, and measures of bronchial 
lability. The history, clinical assessment during an acute 
episode, and response to anti-asthma treatment are argu-
ably the most valuable criteria in reaching a diagnosis. If 
several components of the picture are not suggestive then 
the probability of asthma is reduced. FeNO seems to repre-
sent a small but important piece of this clinical jigsaw.
Other possible niches for FeNO include assessment of 
control, compliance, or the appropriate timing of a reduc-
tion in inhaled corticosteroids.6 11 Crucially, however, well 
conducted trials of adding the measurement of FeNO to 
evidence based management of asthma in children and 
adults have been disappointing, and “getting the basics 
right” remains paramount in childhood asthma.12
Sennhauser FH, Braun-Fahrlander C, Wildhaber JH. The burden of asthma 1 
in children: a European perspective. Paediatr Respir Rev 2005;6:2-7.
Scottish Intercollegiate Guidelines Network. British guideline on the 2 
management of asthma. 2008 (revised June 2009). www.sign.ac.uk/
guidelines/fulltext/101/index.html.
Brodlie M, Spencer D. Growth recovery after withdrawal of inappropriate 3 
inhaled fluticasone proprionate. Pediatr Pulmonol 2008;43:307-8.
Stein RT, Martinez FD. Asthma phenotypes in childhood: lessons from 4 
an epidemiological approach. Paediatr Respir Rev 2004;5:155-61.
Pijnenburg MW, De Jongste JC. Exhaled nitric oxide in childhood 5 
asthma: a review. Clin Exp Allergy 2008;38:246-59.
Pavord ID, Shaw DE, Gibson PG, Taylor DR. Inflammometry to assess 6 
airway diseases. Lancet 2008;372:1017-9.
Bush A, Eber E. The value of FeNO measurement in asthma 7 
management: the motion for Yes, it’s NO—or, the wrong end of the 
stick! Paediatr Respir Rev 2008;9:127-31.
Lex C, Payne DN, Zacharasiewicz A, Li AM, Wilson NM, Hansel TT, et al. 8 
Sputum induction in children with difficult asthma: safety, feasibility, 
and inflammatory cell pattern. Pediatr Pulmonol 2005;39:318-24.
Franklin PJ, Stick SM. The value of FeNO measurement in asthma 9 
management: the motion against FeNO to help manage childhood 
asthma—reality bites. Paediatr Respir Rev 2008;9:122-6.
Sivan Y, Gadish T, Fireman E, Soferman R. The use of exhaled nitric oxide 10 
in the diagnosis of asthma in school children. J Pediatr 2009;155:211-6.
Zacharasiewicz A, Wilson N, Lex C, Erin EM, Li AM, Hansel T, et al. Clinical 11 
use of noninvasive measurements of airway inflammation in steroid 
reduction in children. Am J Respir Crit Care Med 2005;171:1077-82.
Petsky HL, Cates CJ, Li A, Kynaston JA, Turner C, Chang AB. Tailored 12 
interventions based on exhaled nitric oxide versus clinical symptoms 
for asthma in children and adults. Cochrane Database Syst Rev 
2009;(4):CD006340.
BMJ Christmas Appeal 2009
Donate online at www.msf.org.uk/bmjappeal or call 0800 731 6732 (office hours only)
Alternatively post this coupon to:  
BMJ Christmas Appeal, FREEPOST 20939, West Malling, Kent ME19 4BR
Title____    Name_______________________    Address___________________________
___________________________________________________    Postcode____________
I would like to donate £_________________ to Médecins Sans Frontières.
I enclose a cheque/Charity voucher made payable to Médecins Sans Frontières
I give MSF permission to debit my: Visa / Mastercard / Maestro / Amex/ CAF Card 
       
Start Date   /   Expiry Date   /   Issue No. 
3 digit security number 
Signature_________________________________      Date____________ 
MSF’s credit/debit card donations are administered by the Charities Aid Foundation (CAF) 
and will appear as “Donation via CAF” on your statement
B
M
J 
C
h
ri
st
m
a
s 
A
p
p
e
a
l 
C
o
u
p
o
n
GIFT AID
 Make my gift worth more.  I wish my donation, any 
donations I have made in the previous six years 
and any future donations, to be treated as Gift Aid 
donations.  I am a UK taxpayer and have paid income 
tax and/or capital gains tax equal to the tax to be 
reclaimed in this tax year 
 If you would prefer not to receive a thank you letter, 
please tick here
 MSF would like to send you our quarterly newsletter 
Dispatches, which we send to our field volunteers and 
supporters, to keep you up to date with our work.  If you 
do not wish to hear from us, please tick here
Registered Charity No. 1026588 7356
